IP Library › Granted Patent US 10,905,778
Granted Patent B2
US 10,905,778 · App. 16/665,526 · Granted Feb 2, 2021

Methods and compositions for treating a premature stop codon-mediated disorder

Inventors: Jeffery M. Coller (Cleveland, OH); Thomas Sweet (Cleveland, OH)
Assignee: CASE WESTERN RESERVE UNIVERSITY
A61K48/0066A61P25/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,905,778
App. No.
16/665,526
Granted
Feb 2, 2021
Kind
B2
Abstract

Modified tRNAs can be used to express in a mammalian cell a functional gene product encoded by a gene containing a premature stop codon and/or to treat a disease mediated by a premature stop codon.

Claims (7)

1. A method of treating Dravet syndrome in a subject in need thereof, the method comprising:

administering to the subject an effective amount of a tRNA and/or an expression vector capable of expression of the tRNA, wherein the tRNA (i) comprises an anticodon that hybridizes to the premature stop codon, and (ii) is capable of being aminoacylated with an amino acid, thereby to treat the Dravet syndrome in the subject, wherein the subject has an SCN1A gene with premature stop codon mutation selected from c.664C>T, c.1129C>T, c.1492A>T, c.1624C>T, c.1738C>T, c.1837C>T, c.2134C>T, c.2593C>T, c.3637C>T, c.3733C>T, c.3985C>T, c.4573C>T, c.5656C>T, and c.5734C>T; and wherein the tRNA comprises a nucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 16, SEQ ID NO: 17, and SEQ ID NO: 18.

2. The method of claim 1 , wherein the SCN1A gene is caused by a mutation selected from c.1738C>T and c.3985C>T.

3. The method of claim 1 , wherein the amino acid is selected from serine, leucine, glutamine, and arginine.

4. The method of claim 1 , wherein the tRNA comprises the nucleotide sequence selected from SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

5. The method of claim 1 , wherein the expression vector comprises a nucleotide sequence selected from SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 21.

6. The method of claim 1 , wherein the expression vector comprises a nucleotide sequence selected from SEQ ID NO: 5, SEQ ID NO: 8, and SEQ ID NO: 10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 24, 2020
From: LODISH, HARVEY
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 054746/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 23, 2020
From: COLLER, JEFFERY M.; SWEET, THOMAS
To: CASE WESTERN RESERVE UNIVERSITY
Reel/Frame 054737/0433 →
Continuity (5)
Continuation PCTUS2019053260 · Sep 26, 2019
Provisional Application 62805793 · Feb 14, 2019
Provisional Application 62747646 · Oct 18, 2018
Provisional Application 62736834 · Sep 26, 2018
Related Publication 20200101174A1 · Apr 2, 2020
Cited By (3)
US 12,559,749 US 12,565,649 US 12,697,350